3billion Reports 68% YoY Revenue Growth in Q1: Strengthening Growth Foundation Through New Test Launch

• Q1 revenue reaches $2.47 million (KRW 3.36 billion) with 71% from international markets; sustained growth in global rare disease diagnostic demand.
• Operating and net losses narrowed by 16% and 14% YoY, respectively, continuing the trend of narrowing losses and improving financial performance.

SEOUL, South Korea — 3billion (CEO Changwon Kum), an AI-powered rare disease diagnostics company, announced on the 12th that its consolidated revenue for the first quarter of this year reached KRW 3.36 billion, marking a 68% increase compared to the same period last year.

The company reported an operating loss of KRW 1.66 billion and a net loss of KRW 1.47 billion, representing reductions of 16% and 14% respectively over the previous year. Despite the first quarter being a traditional off-season, 3billion maintained a stable growth trajectory by achieving double-digit revenue growth and improving its cost structure.

This performance was driven by the continuous expansion of demand for Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) based genetic testing in the global rare disease market. Exports accounted for 71% of total revenue, with steady demand coming from medical institutions in approximately 75 countries across South America, Europe, the Middle East, and Asia. The rare disease diagnostic service for Neonatal Intensive Care Units (NICU), which launched in earnest last year, also contributed to growth through expanded domestic and international supply.

3billion is also diversifying its business portfolio through new service launches. In Q1, the company introduced ‘Family Insight,’ a family-unit screening service for asymptomatic individuals with a family history of genetic diseases. This move expands the company’s reach from diagnosing rare disease patients to preventative genetic testing.

Looking ahead to the second quarter, the company expects to accelerate revenue growth as it begins participating in domestic and international pilot projects and government tenders for WGS-based newborn screening. Furthermore, as part of the Korea Disease Control and Prevention Agency’s (KDCA) “Rare Disease Diagnosis Support Project,” 3billion has renewed its contract with Pusan National University for WGS-based genetic testing. The revenue from this contract will be reflected starting in Q2. The company anticipates that its annual growth trend will become even more pronounced in the second half of the year as new test lineups contribute to revenue and major contract wins are finalized.

“The first quarter was a period where we once again demonstrated our fundamental business strength by achieving significant revenue growth and improved profitability despite the seasonal off-peak,” said Changwon Kum, CEO of 3billion. “We will maintain this trend of annual performance improvement based on growth engines such as expanding global demand for WES/WGS and the revenue contributions from new lineups like Family Insight and NICU services.”

Meanwhile, 3billion recently secured a solid financial foundation for global expansion and AI-based drug discovery by completing a KRW 30 billion investment round in April. The funding, structured as a mix of Convertible Bonds (CB) and Convertible Preferred Stock (CPS), involved major domestic institutional investors including Kiwoom Securities and GVA Asset Management. The investment was secured with 0% coupon and yield-to-maturity (YTM) rates, further enhancing the company’s financial stability.